BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15867246)

  • 1. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S; McCauley RA; Dexter DW; Hudes GR
    Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines.
    Hiser L; Aggarwal A; Young R; Frankfurter A; Spano A; Correia JJ; Lobert S
    Cell Motil Cytoskeleton; 2006 Jan; 63(1):41-52. PubMed ID: 16362954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
    Wehbe H; Kearney CM; Pinney KG
    Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
    Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR
    Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
    Gan PP; Pasquier E; Kavallaris M
    Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
    Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
    Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
    Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
    Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
    Gan PP; Kavallaris M
    Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling.
    Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K
    Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma.
    Sun CQ; Arnold R; Fernandez-Golarz C; Parrish AB; Almekinder T; He J; Ho SM; Svoboda P; Pohl J; Marshall FF; Petros JA
    Cancer Res; 2006 Sep; 66(17):8542-9. PubMed ID: 16951166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry.
    Verdier-Pinard P; Wang F; Burd B; Angeletti RH; Horwitz SB; Orr GA
    Biochemistry; 2003 Oct; 42(41):12019-27. PubMed ID: 14556633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
    Banerjee A
    Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.